{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002183","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.488724+00:00","generated_at":"2026-06-05T06:09:44.472463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Capricor reports Q4 net loss $0.8M; Phase 3 DMD trial on track for top-line data Q4 2024","bullets":["Q4 2023 net loss $0.8M ($0.02/share) vs $7.7M ($0.31) in Q4 2022; revenue $12.1M from Nippon Shinyaku agreement.","Cash $39.5M at Dec 31, 2023; $10M milestone payment from Nippon Shinyaku received Jan 2024.","Enrollment complete in Cohort A of Phase 3 HOPE-3 trial for CAP-1002 in DMD; positive interim futility analysis.","Cohort B enrollment underway, expected to complete Q2 2024; top-line data from Cohort A expected Q4 2024.","Selected for Project NextGen; NIAID to fund Phase 1 trial of StealthX exosome-based COVID-19 vaccine in late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002183","json":"https://secwatch.observer/filing/0001558370-24-002183.json","markdown":"https://secwatch.observer/filing/0001558370-24-002183.md","text":"https://secwatch.observer/filing/0001558370-24-002183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/0001558370-24-002183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/capr-20240229x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:09:44.472463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2354117920287fe86e7fc1b5c0002fbf4473b45b","claim":"CAPRICOR THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/0001558370-24-002183-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}